Peter Johnson

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

Paul G. Richardson, Albert Oriol, Meral Beksaç et al. · The Lancet Oncology · 2019 · 375 citations · Full text

Hematological Malignancy, Medicine, Hematology +6

Five new pedigrees with inherited RUNX1 mutations causing familial platelet disorder with propensity to myeloid malignancy

Carolyn Owen, Cynthia L. Toze, Anna Koochin et al. · Blood · 2008 · 240 citations · Full text

Autologous Hematopoetic Stem Cell Transplantation for Refractory Crohn Disease

C J Hawkey, Matthieu Allez, Myriam Labopin et al. · JAMA · 2015 · 184 citations · Full text

Molecular MRD status and outcome after transplantation in NPM1-mutated AML

Richard Dillon, Robert K. Hills, Sylvie Freeman et al. · Blood · 2020 · 160 citations · Full text

Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results

Gareth J. Morgan, Faith E. Davies, Walter M. Gregory et al. · Haematologica · 2011 · 159 citations · Full text